The news in brief
The national rollout update reports that the programme is expanding. It does not promise access at every clinic.
The health department's September update describes the expansion of long-acting injectable lenacapavir for HIV prevention after its national launch. The report covers selected public facilities and a dated programme population. It is not an assurance of stock or eligibility at every clinic (Progress on the implementation of Lenacapavir for HIV prevention in SA).
The injection is a PrEP option for preventing HIV. It does not protect against other sexually transmitted infections. Clinical assessment, HIV testing and follow-up remain part of the prevention pathway, including during pregnancy and breastfeeding where relevant (National Consolidated Guidelines for Prevention and Management of HIV, version 2 Adult Primary Care 2026).
Anyone considering this option should ask which local service offers it and how follow-up is organised. A national rollout announcement and the service available on a particular day are two different things (Progress on the implementation of Lenacapavir for HIV prevention in SA).
Going further
This news item is part of a broader topic, which our page South Africa: pregnancy, HIV and STIs and periods covers in detail.
Read the page: South Africa: pregnancy, HIV and STIs and periods